Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Immix Biopharma, Inc. Common Stock Market Cap
From what 1 stock analysts predict, the share price for Immix Biopharma, Inc. Common Stock (IMMX) might increase by 231.75% in the next year. This is based on a 12-month average estimation for IMMX. Price targets go from $7 to $7. The majority of stock analysts believe IMMX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 1 Wall Street analysts have assigned IMMX 1 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Immix Biopharma, Inc. Common Stock to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on IMMX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of IMMX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Robert Burns HC Wainwright & Co. | Buy | $7 | Reiterates | Oct 3, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $7 | Reiterates | Aug 19, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $7 | Reiterates | Jul 26, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $7 | Reiterates | Jul 9, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $7 | Initiates | Jul 1, 2024 |
| Jonathan Aschoff Roth MKM | Buy | $14 | Reiterates | Aug 14, 2023 |
| Jonathan Aschoff Roth MKM | Buy | $14 | Initiates | Feb 22, 2023 |
When did it IPO
2021
Staff Count
14
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
Market Cap
$58.0M
In 2023, IMMX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that IMMX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 25 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Immix Biopharma reported a 75% complete response rate in relapsed/refractory AL Amyloidosis patients treated with NXC-201. Data presentation is scheduled for December 9, 2024, at the ASH Annual Meeting.
Why It Matters - The high response rate of NXC-201 in a challenging patient group highlights its potential value, positioning ImmixBio favorably in the biopharma market and possibly boosting investor interest.
Wed, 02 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Immix Biopharma's NXC-201 CAR-T therapy for relapsed/refractory AL Amyloidosis is advancing in clinical trials, with promising results at 150M and 450M cell doses. It’s the sole one-time CAR-T option in the U.S.
Why It Matters - Advancements in NXC-201 CAR-T therapy could position Immix Biopharma as a leader in treating AL Amyloidosis, potentially driving market interest and affecting stock performance.
Thu, 19 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Immix Biopharma announced that Dr. Raymond Comenzo, an expert in AL amyloidosis, has joined its subsidiary Nexcella's Scientific Advisory Board as of September 19, 2024.
Why It Matters - Dr. Comenzo's appointment enhances Immix Biopharma’s credibility and expertise in AL amyloidosis, potentially boosting investor confidence and driving stock performance.
Wed, 28 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Immix Biopharma added Cleveland Clinic, UC Davis, and Sutter Health as clinical trial sites for its NEXICART-2 trial on AL Amyloidosis, alongside Memorial Sloan Kettering.
Why It Matters - The expansion of clinical trial sites enhances patient access and potential enrollment, signaling strong momentum for ImmixBio's drug development and increasing investor confidence in its pipeline.
Mon, 19 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Immix Biopharma (IMMX) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects, which may lead to a price increase.
Why It Matters - The upgrade to Zacks Rank #2 signals positive sentiment around Immix Biopharma's earnings potential, indicating potential stock price appreciation and attracting investor interest.
Thu, 25 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - An $8 million grant has been awarded for the development of NXC-201 targeting relapsed/refractory AL Amyloidosis.
Why It Matters - The $8 million grant for NXC-201 development signals potential advancements in treating AL Amyloidosis, which could enhance the company's market position and drive stock value.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
